SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.
Last trade$0.7583
Day change-$0.0142 (-1.84%)
Day range$0.756 – $0.859
Volume11,929
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.25M
Price / earnings
—
Price / book
1.14×
Price / sales
1.89×
EV / sales
0.53×
EV / EBITDA
-0.19×
Profitability
Earnings per share
-$1.12
Return on assets
-94.01%
Return on equity
-166.49%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
4.51×
Quick ratio
3.73×
Cash ratio
3.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SNES, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.1M
$770K
$493K
$421K
$690K
$625K
$485K
$501K
Cost of revenue
$301K
$203K
$155K
$188K
$257K
$216K
$172K
$196K
Gross profit
$796K
$567K
$338K
$233K
$433K
$409K
$313K
$305K
Selling, general and administrative
$2.37M
$2.05M
$2.04M
$1.66M
$1.38M
$1.6M
$1.56M
$1.14M
Research and development
$418K
$377K
$422K
$453K
$400K
$427K
$418K
$424K
Total operating expenses
$2.79M
$2.43M
$2.46M
$2.11M
$1.78M
$2.02M
$1.98M
$1.56M
Operating income
-$1.99M
-$1.86M
-$2.12M
-$1.88M
-$1.35M
-$1.61M
-$1.66M
-$1.26M
Interest expense
-$5K
-$5K
-$4K
-$5K
-$6K
-$6K
-$5K
-$7K
Income before taxes
-$1.96M
-$1.83M
-$2.06M
-$1.8M
-$1.3M
-$1.62M
-$1.67M
-$1.26M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.96M
-$1.83M
-$2.06M
-$1.8M
-$1.3M
-$1.62M
-$1.67M
-$1.26M
Net income attributable to common shareholders
-$1.96M
-$1.83M
-$2.06M
-$1.8M
-$1.3M
-$1.62M
-$1.67M
-$1.26M
EBITDA
-$1.96M
-$1.83M
-$2.09M
-$1.85M
-$1.32M
-$1.58M
-$1.62M
-$1.22M
Basic earnings per share
-$0.36
-$0.35
-$0.39
-$0.34
-$0.28
-$0.87
-$1.28
-$1.21
Diluted earnings per share
-$0.36
-$0.35
-$0.39
-$0.34
-$0.28
-$0.87
-$1.28
-$1.21
Recent news
Company coverage with links to the original publishers.
SenesTech, Inc. (NASDAQ: SNES) announced that its Evolve rodent birth control products are now available through Walmart Fulfillment Services (WFS), expanding distribution on Walmart.com. The transition from direct company fulfillment to WFS enables faster delivery, reduces fulfillment costs, and increases product visibility. The company reports that this change is already contributing to increased sales on Walmart.com, supporting its ecommerce growth strategy.
SenesTech's Board of Directors approved an amendment to reduce the number of new shares proposed for its 2018 Equity Incentive Plan from 1.7 million to 1.2 million shares ahead of the June 9, 2026 Annual Meeting of Stockholders. The company cited anticipated equity compensation needs, current market conditions, and stockholder considerations in making this balanced approach to capital management.
SenesTech Inc (NASDAQ: SNES) announced that President and CEO Joel Fruendt plans to retire. The Board will conduct a formal search for a successor, with Fruendt remaining in his position until the search concludes or June 30, 2026, whichever comes first. Dr. Jamie Bechtel has been appointed Interim Executive Chair to support the transition, while interim COO Michael Edell and CFO Tom Chesterman will continue leading day-to-day operations.
SenesTech reported record quarterly revenue of $690,000, a 43% increase from the previous year, with Evolve® Rodent Birth Control product sales growing 77% and representing 85% of total revenue. The company continues to expand across e-commerce, municipal, and retail markets while maintaining a strong cash balance of $10.2 million.
SenesTech completed a warrant exercise transaction, raising approximately $6.3 million in gross proceeds through the issuance of new short-term warrants. The company plans to use the funds for working capital and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.